Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma

Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma

Abstract Background Clinical drawback in checkpoint inhibitors immunotherapy (ICI) of metastatic melanoma (MM) is monitoring clinical benefit. Soluble forms of PD1(sPD1) and PD-L1(sPD-L1) and extracellular vesicles (EVs) expressing PD1 and PD-L1 have recently emerged as predictive biomarkers of resp...

Full description

Bibliographic Details
Main Authors:	Simona Serratì, Roberta Di Fonte, Letizia Porcelli, Simona De Summa, Ivana De Risi, Livia Fucci, Eustachio Ruggieri, Tommaso Maria Marvulli, Sabino Strippoli, Rossella Fasano, Tania Rafaschieri, Gabriella Guida, Michele Guida, Amalia Azzariti
Format:	Article
Language:	English
Published:	BMC 2023-09-01
Series:	Journal of Experimental & Clinical Cancer Research
Subjects:	Extracellular vesicles Metastatic melanoma Predictor of anti-PD1 response Anti-PD1 resistance
Online Access:	https://doi.org/10.1186/s13046-023-02808-9

Similar Items

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
by: Amalia Azzariti, et al.
Published: (2025-02-01)

Metastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167)
by: Yuantai Li, et al.
Published: (2025-01-01)

Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab
by: Camélia Benhayoun, et al.
Published: (2024-08-01)

Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case series
by: Mina Nikanjam, et al.
Published: (2022-08-01)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
by: Paolo A. Ascierto, et al.
Published: (2017-08-01)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01)

Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy
by: Sinne Søberg Brun, et al.
Published: (2024-04-01)

Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy
by: Mithunah Krishnamoorthy, et al.
Published: (2021-05-01)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
by: Roman Groisberg, et al.
Published: (2017-12-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy
by: Xinran Gao, et al.
Published: (2024-03-01)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4<sup>+</sup> T Cells
by: Reem Saleh, et al.
Published: (2019-10-01)

Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment
by: Clio Dessinioti, et al.
Published: (2023-10-01)

Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population–based analysis
by: Jingjing Zhao, et al.
Published: (2022-12-01)

Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFNγ Responses of HIV-Infected Persons on Antiretroviral Therapy
by: Natalie Fischhaber, et al.
Published: (2023-01-01)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
by: Jacek Mackiewicz, et al.
Published: (2017-03-01)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
by: Kohei Fujita, et al.
Published: (2020-01-01)

Small-Cell Lung Cancer: Is Liquid Biopsy a New Tool Able to Predict the Efficacy of Immunotherapy?
by: Rossella Fasano, et al.
Published: (2024-03-01)

HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
by: Jibin Zhang, et al.
Published: (2020-01-01)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
by: Faisal K. Alkholifi, et al.
Published: (2022-11-01)

Comparison of treatment outcome between first‐line combination immunotherapy (anti‐PD‐L1 or anti‐PD1) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital
by: Danainut Naratornsirakul, et al.
Published: (2024-07-01)

The current status and future of targeted-immune combination for hepatocellular carcinoma
by: Liyuan Hao, et al.
Published: (2024-08-01)

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis
by: Joe Q. Wei, et al.
Published: (2023-06-01)

Cutaneous angiosarcoma: A review of current evidence for treatment with checkpoint inhibitors
by: Lucy Guan, et al.
Published: (2023-03-01)

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
by: Relinde I. Y. Lieverse, et al.
Published: (2020-06-01)

Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer
by: Vida Vafaizadeh, et al.
Published: (2020-03-01)

Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
by: Masatoshi Kudo
Published: (2022-05-01)

Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
by: Martin Rao, et al.
Published: (2017-03-01)

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
by: Sepe P, et al.
Published: (2020-11-01)

Oxymatrine Inhibits PD-L1 by Downregulating IFN-γ to Promote Ferroptosis and Enhance Anti-PD-L1 Efficacy in Liver Cancer
by: Nong Y, et al.
Published: (2024-12-01)

Radiation recall pneumonitis from immune checkpoint inhibitors after extra pulmonary radiation
by: Leslie E. Kao, et al.
Published: (2023-10-01)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019-12-01)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
by: Alessio Cortellini, et al.
Published: (2019-02-01)

The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis
by: Li Y, et al.
Published: (2021-02-01)

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
by: Afsheen Raza, et al.
Published: (2023-05-01)

Checkpoint inhibitor responses can be regulated by the gut microbiota – A systematic review
by: Mariam Zeriouh, et al.
Published: (2023-09-01)

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
by: Tao Wang, et al.
Published: (2022-05-01)

The use of immunotherapy in the treatment of melanoma
by: Tala Achkar, et al.
Published: (2017-04-01)

Optimum fractionation of radiation to combine PD‐1 blockade
by: Feifei Teng, et al.
Published: (2023-06-01)

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
by: Katarzyna Tomela, et al.
Published: (2023-03-01)